Please ensure Javascript is enabled for purposes of website accessibility

2 Biotechs Trouncing the Market

By Dave Williamson – Updated Apr 7, 2017 at 1:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

These stocks had outsized moves.

The biotech week kicked off with a bang, not because of any macro factors like a new Federal Reserve program of monetary stimulus, or economic data emanating from Europe.  BioSante (Nasdaq: BPAX), up 22%, and Savient (Nasdaq: SVNT), up 13%, rose on no specific news. However, BioSante recently halted a safety trial for LibiGel, believing it has enough data to get an FDA green light, and Savient is awaiting EU approval for its gout drug Krystexxa.

Two other biotechs, though, had big moves today for company-specific reasons. Let's dive into each story and highlight key investor takeaways.

Complete Genomics (Nasdaq: GNOM) finished up 13% after agreeing to be purchased by Chinese gene-sequencing operator BGI-Shenzen for $3.15 per share. While today's pop may seem small, shares sit only $0.13 under the deal price, and it's important to remember that it's more than a 50% premium to when Complete Genomics announced it was looking for acquirers.

Not that it's any consolation for long-term holders, as shares traded at about $15 as recently as last summer. The company remains wildly unprofitable, but its more accurate, albeit slower, technology gives BGI not only a U.S. presence but also leverage against Illumina (Nasdaq: ILMN), its main supplier. Although it will operate as a separate entity, it's still a disappointing end for the promising small sequencer.

What is the opposite of disappointing? Hitting an all-time high. Investors in Jazz Pharmaceuticals (Nasdaq: JAZZ) are enjoying the sounds of success after a federal judge upheld the company's position, in a critical patent lawsuit for narcolepsy drug Xyrem. It's unlikely that the FDA will approve Roxane Laboratories' generic version given this ruling. Xyrem is Jazz's flagship product, and at $233.3 million in 2011 sales, it brought in the vast majority of its revenue. For the success of the company, defending that ground was a must.

Investors are attracted to biotechs like Jazz since they hold the allure of substantial short-term gains. But there's more than one approach to building long-term wealth and retiring well. In our free report "3 Stocks That Will Help You Retire Rich," we reveal some stocks that could help you as well as some winning wealth-building strategies. Click here to keep reading.

David Williamson holds no position in any company mentioned. Check out his holdings and a short bio. Motley Fool newsletter services have recommended buying shares of Illumina. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

ANI Pharmaceuticals Stock Quote
ANI Pharmaceuticals
$33.49 (1.98%) $0.65
Illumina Stock Quote
$212.72 (-2.65%) $-5.80
Jazz Pharmaceuticals Stock Quote
Jazz Pharmaceuticals
$139.09 (1.98%) $2.70

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.